180 related articles for article (PubMed ID: 12414868)
1. Vascular reactivity in hypogonadal men is reduced by androgen substitution.
Zitzmann M; Brune M; Nieschlag E
J Clin Endocrinol Metab; 2002 Nov; 87(11):5030-7. PubMed ID: 12414868
[TBL] [Abstract][Full Text] [Related]
2. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study.
Zitzmann M; Depenbusch M; Gromoll J; Nieschlag E
J Clin Endocrinol Metab; 2003 May; 88(5):2049-54. PubMed ID: 12727953
[TBL] [Abstract][Full Text] [Related]
3. Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy.
Bernini G; Versari D; Moretti A; Virdis A; Ghiadoni L; Bardini M; Taurino C; Canale D; Taddei S; Salvetti A
J Clin Endocrinol Metab; 2006 May; 91(5):1691-7. PubMed ID: 16492703
[TBL] [Abstract][Full Text] [Related]
4. Physiological testosterone replacement and arterial endothelial function in men.
Sader MA; Griffiths KA; Skilton MR; Wishart SM; Handelsman DJ; Celermajer DS
Clin Endocrinol (Oxf); 2003 Jul; 59(1):62-7. PubMed ID: 12807505
[TBL] [Abstract][Full Text] [Related]
5. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
[TBL] [Abstract][Full Text] [Related]
6. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system.
Dobs AS; Bachorik PS; Arver S; Meikle AW; Sanders SW; Caramelli KE; Mazer NA
J Clin Endocrinol Metab; 2001 Mar; 86(3):1026-33. PubMed ID: 11238481
[TBL] [Abstract][Full Text] [Related]
7. Impact on lipoprotein profile after long-term testosterone replacement in hypogonadal men.
Berg G; Schreier L; Geloso G; Otero P; Nagelberg A; Levalle O
Horm Metab Res; 2002 Feb; 34(2):87-92. PubMed ID: 11972293
[TBL] [Abstract][Full Text] [Related]
8. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
9. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting.
Grinspoon S; Corcoran C; Stanley T; Katznelson L; Klibanski A
J Clin Endocrinol Metab; 1998 Dec; 83(12):4251-6. PubMed ID: 9851759
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
[TBL] [Abstract][Full Text] [Related]
11. Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study.
Rolf C; von Eckardstein S; Koken U; Nieschlag E
Eur J Endocrinol; 2002 Apr; 146(4):505-11. PubMed ID: 11916618
[TBL] [Abstract][Full Text] [Related]
12. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.
Wang C; Eyre DR; Clark R; Kleinberg D; Newman C; Iranmanesh A; Veldhuis J; Dudley RE; Berman N; Davidson T; Barstow TJ; Sinow R; Alexander G; Swerdloff RS
J Clin Endocrinol Metab; 1996 Oct; 81(10):3654-62. PubMed ID: 8855818
[TBL] [Abstract][Full Text] [Related]
13. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting.
Grinspoon S; Corcoran C; Lee K; Burrows B; Hubbard J; Katznelson L; Walsh M; Guccione A; Cannan J; Heller H; Basgoz N; Klibanski A
J Clin Endocrinol Metab; 1996 Nov; 81(11):4051-8. PubMed ID: 8923860
[TBL] [Abstract][Full Text] [Related]
14. Endogenous testosterone and brachial artery endothelial function in middle-aged men with symptoms of late-onset hypogonadism.
Mäkinen JI; Perheentupa A; Irjala K; Pöllänen P; Mäkinen J; Huhtaniemi I; Raitakari OT
Aging Male; 2011 Dec; 14(4):237-42. PubMed ID: 21831030
[TBL] [Abstract][Full Text] [Related]
15. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.
Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N
J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832
[TBL] [Abstract][Full Text] [Related]
16. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men.
Yaron M; Greenman Y; Rosenfeld JB; Izkhakov E; Limor R; Osher E; Shenkerman G; Tordjman K; Stern N
Eur J Endocrinol; 2009 May; 160(5):839-46. PubMed ID: 19174534
[TBL] [Abstract][Full Text] [Related]
17. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
Zitzmann M; Nieschlag E
J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
[TBL] [Abstract][Full Text] [Related]
20. Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis.
Karakitsos D; Patrianakos AP; De Groot E; Boletis J; Karabinis A; Kyriazis J; Samonis G; Parthenakis FI; Vardas PE; Daphnis E
Am J Nephrol; 2006; 26(6):536-43. PubMed ID: 17159341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
